Company Information

Market
HKEX Main Board
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
HK0000145638
Southbound Connect
Shanghai · Shenzhen

Industry

Innovative Drugs & Biologics 2.03%
124 stocks in this industry
Down 91 Up 17
Industry RankingsValue (HKD)Rank
Revenue (Last FY)1.37B48/112
Net Profit (Last FY)358.77M32/125
ROE (Last FY)9.48%29/117

Change is the 2026-11-13 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
Yan Han Executive Director
Yue Zheng Executive Director
Wang Chi Executive Director
Feng Li Non-Executive Director
Tsang Yok Sing, Jasper Independent Non-Executive Director
Xu Hong Xi Independent Non-Executive Director
Chan Ngai Chi Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2025-09-04.

About this page

This page shows TONGRENTANGCM (03613) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect